{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T16:21:12Z","timestamp":1648916472459},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s00105-005-1005-7","type":"journal-article","created":{"date-parts":[[2005,8,18]],"date-time":"2005-08-18T05:23:41Z","timestamp":1124342621000},"page":"831-838","source":"Crossref","is-referenced-by-count":0,"title":["Infliximab"],"prefix":"10.1007","volume":"56","author":[{"given":"R.","family":"M\u00f6ssner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1005_CR1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B et al. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"1005_CR2","first-page":"107","volume":"14","author":"Augustin","year":"2004","unstructured":"Augustin M, Lange S, Wenninger K et al. (2004) Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a thereshold system. Eur J Dermatol 14:107\u2013113","journal-title":"Eur J Dermatol"},{"key":"1005_CR3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD et al. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842\u20131847","journal-title":"Lancet"},{"key":"1005_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","volume":"53","author":"Di Sabatino","year":"2004","unstructured":"Di Sabatino A, Ciccocioppo R, Cinque B et al. (2004) Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn\u2019s disease. Gut 53:70\u201377","journal-title":"Gut"},{"key":"1005_CR5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","volume":"152","author":"Feldman","year":"2005","unstructured":"Feldman SR, Gordon KB, Bala M et al. (2005) Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 152:954\u2013960","journal-title":"Br J Dermatol"},{"key":"1005_CR6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534\u2013542","journal-title":"J Am Acad Dermatol"},{"key":"1005_CR7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","volume":"349","author":"Heydendael","year":"2003","unstructured":"Heydendael VM, Spuls PI, Opmeer BC et al. (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349:658\u2013365","journal-title":"N Engl J Med"},{"key":"1005_CR8","first-page":"1213","volume":"32","author":"Jacobsson","year":"2005","unstructured":"Jacobsson LT, Turesson C, Gulfe A et al. (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213\u20131218","journal-title":"J Rheumatol"},{"key":"1005_CR9","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939\u20131950","journal-title":"Arthritis Rheum"},{"key":"1005_CR10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"Kindler","year":"1989","unstructured":"Kindler V, Sappino AP, Grau GE et al. (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731\u2013740","journal-title":"Cell"},{"key":"1005_CR11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/B:EJEP.0000020447.59150.f9","volume":"19","author":"Mallbris","year":"2004","unstructured":"Mallbris L, Akre O, Granath F et al. (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19:225\u2013230","journal-title":"Eur J Epidemiol"},{"key":"1005_CR12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX et al. (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264\u20132272","journal-title":"Arthritis Rheum"},{"key":"1005_CR13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.det.2004.03.016","volume":"22","author":"Mukhtar","year":"2004","unstructured":"Mukhtar R, Choi J, Koo JY (2004) Quality-of life issues in psoriasis. Dermatol Clin 22:389\u2013395","journal-title":"Dermatol Clin"},{"key":"1005_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-4362.2002.01543.x","volume":"41","author":"Newland","year":"2002","unstructured":"Newland MR, Weinstein A, Kerdel F (2002) Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41:449\u2013452","journal-title":"Int J Dermatol"},{"key":"1005_CR15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","volume":"34","author":"Peters","year":"2004","unstructured":"Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585\u2013592","journal-title":"Semin Arthritis Rheum"},{"key":"1005_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML et al. (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:401\u2013407","journal-title":"J Am Acad Dermatol"},{"key":"1005_CR17","unstructured":"Reich K, Nestle JP, Papp K et al. (2005) Wirksamkeit und Sicherheit von Infliximab bei Psoriasis Patienten: Ergebnisse einer Phase-III-Studie. JDDG 3 [Suppl 1]:S177 (abstract)"},{"key":"1005_CR18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1067\/mjd.2003.446","volume":"48","author":"Reynoso-von Drateln","year":"2003","unstructured":"Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR et al. (2003) Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48:882\u2013885","journal-title":"J Am Acad Dermatol"},{"key":"1005_CR19","first-page":"334","volume":"78","author":"Saunders","year":"2000","unstructured":"Saunders BM, Cooper AM (2000) Restraining mycobacteria: role of granulomas in mycobacterial infections Immunol. Cell Biol 78:334\u2013341","journal-title":"Cell Biol"},{"key":"1005_CR20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-2004-818448","volume":"58","author":"Schaberg","year":"2004","unstructured":"Schaberg T, Hauer B, Haas WH et al. (2004) Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany. Pneumologie 58:255\u2013270","journal-title":"Pneumologie"},{"key":"1005_CR21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.2004.05719.x","volume":"150","author":"Schmick","year":"2004","unstructured":"Schmick K, Grabbe J (2004) Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 150:367","journal-title":"Br J Dermatol"},{"key":"1005_CR22","first-page":"report","volume":"infliximab","author":"Starmans-Kool","year":"2005","unstructured":"Starmans-Kool MJ, Peeters HR, Houben HH (2005) Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int (Epub ahead of print)","journal-title":"Pustular skin lesions in patients treated with"},{"key":"1005_CR23","first-page":"439","volume":"3","author":"Thurber","year":"2004","unstructured":"Thurber M, Feasel A, Stroehlein J, Hymes SR (2004) Pustular psoriasis induced by infliximab. J Drugs Dermatol 3:439\u2013440","journal-title":"J Drugs Dermatol"},{"key":"1005_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","volume":"34","author":"Wallis","year":"2005","unstructured":"Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34\u201338","journal-title":"Semin Arthritis Rheum"},{"key":"1005_CR25","unstructured":"Zschocke I, Hammelmann U, Augustin M (2005) Evaluation of clinical benefit in dermatological therapy Bewertung von Therapieerfolg aus Arzt- und Patientenperspektive bei Psoriasis und atopischer Dermatitis. Hautarzt (Epub ahead of print)"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-1005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-005-1005-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-1005-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:07Z","timestamp":1558568227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-005-1005-7"}},"subtitle":["Stellenwert in der Therapie der Psoriasis"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s00105-005-1005-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}